Developer docs
API playgroundTry for free, no card

Search company profiles

LymeAlert

Full company profile

uuid006dknw

Namestring
LymeAlert
Legal namestring
LymeAlert
Websiteurl
lymealert.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

LymeAlert is an MIT-affiliated, venture-backed startup developing an at-home tick testing kit for early detection of Lyme disease risk. The product is a single-use lateral flow assay that detects Borrelia burgdorferi, the pathogen responsible for Lyme disease, directly in a removed tick rather than in a person or animal. Each kit includes the proprietary Tick Crusher device, which processes up to five ticks to the correct particle size for the chemically infused paper test strip to function, and produces results in approximately 30 minutes. A companion mobile application uses smartphone-based computer vision to interpret faint color changes on the test strip, connects users to third-party telehealth and televet providers, and aggregates anonymized test data for tick-borne disease hotspot mapping.

The company targets a deliberately broad consumer and prosumer base segmented into families and parents, pet and animal owners, equestrians, outdoor enthusiasts, and veterinary/medical practices. Distribution is primarily direct-to-consumer via the company's own e-commerce site (lymealert.com) with preorders open ahead of an August 2026 shipping launch, alongside a wholesale channel supplying veterinary clinics, medical practices, research institutions, and distributors. Pricing is anchored at $49.99 per single kit, with 3-Kit and 6-Kit bundles priced up to $254.95, positioning the product as a faster and cheaper alternative to lab testing ($50–$450 with multi-day turnaround) and to early-infection blood tests that carry 22–40% accuracy limitations within the critical 72-hour CDC treatment window.

LymeAlert is led by co-founders Erin Dawicki (CEO, former Boston Children's Hospital clinician and MIT Sloan Fellow), Dr. Michelle Ewy (CSO, Air Force veteran with 20+ years in diagnostic development), Brenda Ong (COO), and Lewis Shotton (Lead Researcher, bioengineer). The executive bench also includes CFO Craig McLaughlin (CPA), fractional CMO Casey Tilli, and a product leader. The company is headquartered in Massachusetts, governed under Massachusetts law, employs 1–10 people, and has raised early-stage venture funding from Fortify Ventures along with support from MIT Sandbox, Bay Area Lyme Ventures, and the Pet Care Innovation accelerator. Recognition includes MIT Sloan 'Startup to Watch' (2024), the CIC Social Impact Growth Stage Judge's Choice Award (2026), first place at the Outside Ignite pitch competition (2026), and a 2026 Presidential Leadership Scholar designation for the CEO. Revenue has not yet been generated and no specific funding amounts have been disclosed.

Short descriptiontext

LymeAlert is an MIT-affiliated startup selling an at-home lateral flow assay kit that detects Borrelia burgdorferi in removed ticks in approximately 30 minutes. It serves families, pet owners, equestrians, outdoor enthusiasts, and veterinary practices via DTC e-commerce and wholesale channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home diagnostic kits, lyme disease testing, lateral flow assay, tick-borne pathogen detection, veterinary diagnostic products
Industry3 codes
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAKAGAL
Tick-Borne & Vector-Borne Diseases
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
At-Home Diagnostic Test Kits
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Test Kit Hardware Sales
TypeHardware Sales
Description

The company generates revenue primarily through the sale of its at-home Lyme disease tick testing kits. Products include single kits and multi-pack bundles sold directly to consumers and through wholesale channels.

lymealert.com
2Telehealth Services (Potential)
TypeProfessional Services
Description

The companion app provides connections to telehealth providers for guidance on next steps after positive test results. Telehealth services are typically billed through the user's insurance company and provided by third-party providers, not directly by LymeAlert.

lymealert.com
3Data Analytics and Mapping
TypeData Monetisation
Description

The company collects anonymized data from tests and plans to use hotspot mapping to help improve awareness of tick-borne disease risk regions.

lymealert.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations
Pricing details3 tiers
1Single Kit - Individual test kit for one-time use
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$49.99 per single kit. Includes 1 Single Use Test with Tick Crusher, Processing Solution Tube, and Test Strip. Tests up to 5 ticks per kit.

lymealert.com
23-Kit Bundle - Multi-pack for families or multiple tests
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Bundle pricing offering savings compared to individual kits. Price range starts at $49.99 through $254.95.

lymealert.com
36-Kit Bundle - Large multi-pack for frequent outdoor users or practices
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Largest bundle option with pricing within the $49.99 - $254.95 range. Designed for veterinary practices, research institutions, distributors, and families.

lymealert.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LymeAlert designs and sells an at-home lateral flow assay test kit that detects Borrelia burgdorferi (the pathogen that causes Lyme disease) in ticks within approximately 30 minutes. Each kit includes the proprietary Tick Crusher device, a Processing Solution Tube, and a Test Strip, and can test up to five ticks. A companion mobile application provides computer-vision-based result interpretation, telehealth service connections, and hotspot mapping for tick-borne disease risk areas.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LymeAlert offers a single core product—the At-Home Tick Testing Kit—augmented by a companion mobile application. The test kit is a lateral flow assay designed to detect Borrelia burgdorferi in ticks within approximately 30 minutes. The kit is sold in three configurations (Single Kit, 3-Kit Bundle, 6-Kit Bundle) and includes the proprietary Tick Crusher, Processing Solution Tube, and Test Strip. The companion mobile app provides computer-vision-based test strip scanning for definitive results, telehealth/televet connections, and tick-borne disease hotspot mapping. The product tests the tick (not the person or animal) and is designed for use by humans, pets, and animals.

Product and service2 records
1LymeAlert At-Home Tick Testing Kit
CategoryAt-Home Diagnostic Test Kits
Description

An at-home lateral flow assay test kit that detects Borrelia burgdorferi (the pathogen that causes Lyme disease) in ticks within approximately 30 minutes. Users place a removed tick into the included Tick Crusher, activate the test strip, and interpret results visually or through the companion mobile application. Each single-use kit tests up to five ticks. Sold as Single Kit, 3-Kit Bundle, and 6-Kit Bundle.

2LymeAlert Mobile Application
CategoryCompanion Mobile Application
Description

A companion mobile application to the tick test kit that provides definitive test result scanning via smartphone camera using computer vision, telehealth/televet service connections for guidance on next steps, and hotspot mapping to track tick-borne disease expansion and identify high-risk geographic areas.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

LymeAlert joined Pet Care Innovation's accelerator program along with ChefPaw, PetPax Co., and CoVet for grant funding. This suggests strategic alignment and accelerator support from the pet care ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest U.S. clinical reference lab, offering physician-ordered Lyme and tick-borne disease serology. Represents the incumbent workflow LymeAlert is attempting to disintermediate for early detection, and a potential channel partner through physician offices.

TypeDirect peer
Description

Mail-in tick testing service operated out of UMass Amherst that screens removed ticks for Borrelia burgdorferi and other pathogens. Most direct head-to-head competitor to LymeAlert's value proposition, but trades off speed (3–7 day turnaround) for broader multi-pathogen panels.

3Abbott
TypeBroad incumbent
Description

Global diagnostics leader with the Binax lateral flow franchise and rapid test manufacturing scale. Could enter the tick-borne LFT category and overwhelm LymeAlert on distribution and pharmacy-shelf placement.

TypeEmerging player
Description

Rapid molecular diagnostics company with a focus on decentralized CLIA-waived infectious disease testing. Emerging competitive threat if it extends rapid POC STI/respiratory testing into tick-borne disease, and a potential strategic acquirer for LymeAlert's consumer brand.

TypeBroad incumbent
Description

Major U.S. clinical lab with Lyme disease and tick-borne serology panels. Same incumbent dynamics as Quest — the entrenched lab-based standard LymeAlert positions against on speed and convenience, with Pixel by LabCorp adding a DTC adjacency.

TypeDirect peer
Description

At-home diagnostics company that pairs smartphone-based computer vision with rapid test strips for UTI and kidney disease. Closely mirrors LymeAlert's smartphone-CV-over-lateral-flow approach and is a strong template for the digital diagnostic experience.

7IGeneX
TypeBroad incumbent
Description

Specialty reference lab focused on tick-borne disease testing (Lyme, Babesia, Bartonella, etc.). Operates as a CLIA-certified lab rather than a consumer product, but competes for the same end-patient/physician decision and is a likely B2B channel partner or acquirer for LymeAlert.

TypeDirect peer
Description

Mail-in tick identification and pathogen testing service. Targets the same 'test the tick' use case as LymeAlert with an established consumer/agency base, again competing primarily on turnaround time and price rather than on integrated sample-prep hardware.

9Cue Health
TypeDirect peer
Description

At-home molecular diagnostic platform with connected reader and app-based results. Comparable consumer-grade hardware + app + cloud data architecture, though Cue targets respiratory and other infectious diseases using molecular rather than lateral flow chemistry.

TypeDirect peer
Description

Direct-to-consumer at-home diagnostic testing brand (parent company Everly Health). Overlapping business model — DTC health tests with digital results — but focused on blood/urine biomarkers rather than tick-borne pathogen detection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LymeAlert

At-Home Diagnostic Test Kitslymealert.com

LymeAlert is an MIT-affiliated startup selling an at-home lateral flow assay kit that detects Borrelia burgdorferi in removed ticks in approximately 30 minutes. It serves families, pet owners, equestrians, outdoor enthusiasts, and veterinary practices via DTC e-commerce and wholesale channels.

What LymeAlert does

LymeAlert is an MIT-affiliated, venture-backed startup developing an at-home tick testing kit for early detection of Lyme disease risk. The product is a single-use lateral flow assay that detects Borrelia burgdorferi, the pathogen responsible for Lyme disease, directly in a removed tick rather than in a person or animal. Each kit includes the proprietary Tick Crusher device, which processes up to five ticks to the correct particle size for the chemically infused paper test strip to function, and produces results in approximately 30 minutes. A companion mobile application uses smartphone-based computer vision to interpret faint color changes on the test strip, connects users to third-party telehealth and televet providers, and aggregates anonymized test data for tick-borne disease hotspot mapping.

The company targets a deliberately broad consumer and prosumer base segmented into families and parents, pet and animal owners, equestrians, outdoor enthusiasts, and veterinary/medical practices. Distribution is primarily direct-to-consumer via the company's own e-commerce site (lymealert.com) with preorders open ahead of an August 2026 shipping launch, alongside a wholesale channel supplying veterinary clinics, medical practices, research institutions, and distributors. Pricing is anchored at $49.99 per single kit, with 3-Kit and 6-Kit bundles priced up to $254.95, positioning the product as a faster and cheaper alternative to lab testing ($50–$450 with multi-day turnaround) and to early-infection blood tests that carry 22–40% accuracy limitations within the critical 72-hour CDC treatment window.

LymeAlert is led by co-founders Erin Dawicki (CEO, former Boston Children's Hospital clinician and MIT Sloan Fellow), Dr. Michelle Ewy (CSO, Air Force veteran with 20+ years in diagnostic development), Brenda Ong (COO), and Lewis Shotton (Lead Researcher, bioengineer). The executive bench also includes CFO Craig McLaughlin (CPA), fractional CMO Casey Tilli, and a product leader. The company is headquartered in Massachusetts, governed under Massachusetts law, employs 1–10 people, and has raised early-stage venture funding from Fortify Ventures along with support from MIT Sandbox, Bay Area Lyme Ventures, and the Pet Care Innovation accelerator. Recognition includes MIT Sloan 'Startup to Watch' (2024), the CIC Social Impact Growth Stage Judge's Choice Award (2026), first place at the Outside Ignite pitch competition (2026), and a 2026 Presidential Leadership Scholar designation for the CEO. Revenue has not yet been generated and no specific funding amounts have been disclosed.

LymeAlert firmographics

Firmographics
Name
LymeAlert
Legal name
LymeAlert
Website
https://lymealert.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
LymeAlert is an MIT-affiliated startup selling an at-home lateral flow assay kit that detects Borrelia burgdorferi in removed ticks in approximately 30 minutes. It serves families, pet owners, equestrians, outdoor enthusiasts, and veterinary practices via DTC e-commerce and wholesale channels.
Ownership category
akta.pro rank

LymeAlert industry classification

Industry
Product category
At-Home Diagnostic Test Kits
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAKAGAL
Tick-Borne & Vector-Borne Diseases
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays

Keywords

  • At-home diagnostic kits
  • Lyme disease testing
  • Lateral flow assay
  • Tick-borne pathogen detection
  • Veterinary diagnostic products

Where LymeAlert is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LymeAlert business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

  1. Test Kit Hardware Sales: The company generates revenue primarily through the sale of its at-home Lyme disease tick testing kits. Products include single kits and multi-pack bundles sold directly to consumers and through wholesale channels.
  2. Telehealth Services (Potential): The companion app provides connections to telehealth providers for guidance on next steps after positive test results. Telehealth services are typically billed through the user's insurance company and provided by third-party providers, not directly by LymeAlert.
  3. Data Analytics and Mapping: The company collects anonymized data from tests and plans to use hotspot mapping to help improve awareness of tick-borne disease risk regions.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSingle Kit - Individual test kit for one-time use
Unit PricingPay-as-you-go3-Kit Bundle - Multi-pack for families or multiple tests
Unit PricingPay-as-you-go6-Kit Bundle - Large multi-pack for frequent outdoor users or practices

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

LymeAlert product offering

Product offering

Core offering

LymeAlert designs and sells an at-home lateral flow assay test kit that detects Borrelia burgdorferi (the pathogen that causes Lyme disease) in ticks within approximately 30 minutes. Each kit includes the proprietary Tick Crusher device, a Processing Solution Tube, and a Test Strip, and can test up to five ticks. A companion mobile application provides computer-vision-based result interpretation, telehealth service connections, and hotspot mapping for tick-borne disease risk areas.

Product overview

LymeAlert offers a single core product—the At-Home Tick Testing Kit—augmented by a companion mobile application. The test kit is a lateral flow assay designed to detect Borrelia burgdorferi in ticks within approximately 30 minutes. The kit is sold in three configurations (Single Kit, 3-Kit Bundle, 6-Kit Bundle) and includes the proprietary Tick Crusher, Processing Solution Tube, and Test Strip. The companion mobile app provides computer-vision-based test strip scanning for definitive results, telehealth/televet connections, and tick-borne disease hotspot mapping. The product tests the tick (not the person or animal) and is designed for use by humans, pets, and animals.

Differentiator

Problem solved

Functional benefit

Products and services

  • LymeAlert At-Home Tick Testing Kit An at-home lateral flow assay test kit that detects Borrelia burgdorferi (the pathogen that causes Lyme disease) in ticks within approximately 30 minutes. Users place a removed tick into the included Tick Crusher, activate the test strip, and interpret results visually or through the companion mobile application. Each single-use kit tests up to five ticks. Sold as Single Kit, 3-Kit Bundle, and 6-Kit Bundle.
  • LymeAlert Mobile Application A companion mobile application to the tick test kit that provides definitive test result scanning via smartphone camera using computer vision, telehealth/televet service connections for guidance on next steps, and hotspot mapping to track tick-borne disease expansion and identify high-risk geographic areas.

Companies that use LymeAlert

Customer profile

Segments5 records

Ideal customer profiles4 records

LymeAlert technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

LymeAlert partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pet Care InnovationminorStrategic or Co-development PartnerLymeAlert joined Pet Care Innovation's accelerator program along with ChefPaw, PetPax Co., and CoVet for grant funding. This suggests strategic alignment and accelerator support from the pet care ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

LymeAlert competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: Largest U.S. clinical reference lab, offering physician-ordered Lyme and tick-borne disease serology. Represents the incumbent workflow LymeAlert is attempting to disintermediate for early detection, and a potential channel partner through physician offices.
  • Abbott: Global diagnostics leader with the Binax lateral flow franchise and rapid test manufacturing scale. Could enter the tick-borne LFT category and overwhelm LymeAlert on distribution and pharmacy-shelf placement.
  • Labcorp: Major U.S. clinical lab with Lyme disease and tick-borne serology panels. Same incumbent dynamics as Quest — the entrenched lab-based standard LymeAlert positions against on speed and convenience, with Pixel by LabCorp adding a DTC adjacency.
  • IGeneX: Specialty reference lab focused on tick-borne disease testing (Lyme, Babesia, Bartonella, etc.). Operates as a CLIA-certified lab rather than a consumer product, but competes for the same end-patient/physician decision and is a likely B2B channel partner or acquirer for LymeAlert.

Direct peers

  • TickReport (UMass Amherst): Mail-in tick testing service operated out of UMass Amherst that screens removed ticks for Borrelia burgdorferi and other pathogens. Most direct head-to-head competitor to LymeAlert's value proposition, but trades off speed (3–7 day turnaround) for broader multi-pathogen panels.
  • Scanwell Health: At-home diagnostics company that pairs smartphone-based computer vision with rapid test strips for UTI and kidney disease. Closely mirrors LymeAlert's smartphone-CV-over-lateral-flow approach and is a strong template for the digital diagnostic experience.
  • TICKNOLOGY: Mail-in tick identification and pathogen testing service. Targets the same 'test the tick' use case as LymeAlert with an established consumer/agency base, again competing primarily on turnaround time and price rather than on integrated sample-prep hardware.
  • Cue Health: At-home molecular diagnostic platform with connected reader and app-based results. Comparable consumer-grade hardware + app + cloud data architecture, though Cue targets respiratory and other infectious diseases using molecular rather than lateral flow chemistry.
  • Everlywell: Direct-to-consumer at-home diagnostic testing brand (parent company Everly Health). Overlapping business model — DTC health tests with digital results — but focused on blood/urine biomarkers rather than tick-borne pathogen detection.

Emerging players

  • Binx Health: Rapid molecular diagnostics company with a focus on decentralized CLIA-waived infectious disease testing. Emerging competitive threat if it extends rapid POC STI/respiratory testing into tick-borne disease, and a potential strategic acquirer for LymeAlert's consumer brand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

LymeAlert social profiles

Digital presence

LymeAlert financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LymeAlert leadership team

Management profile

Number of profiles

Profiles8 records

LymeAlert funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LymeAlert M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LymeAlert

What does LymeAlert do?

LymeAlert designs and sells an at-home lateral flow assay test kit that detects Borrelia burgdorferi (the pathogen that causes Lyme disease) in ticks within approximately 30 minutes. Each kit includes the proprietary Tick Crusher device, a Processing Solution Tube, and a Test Strip, and can test up to five ticks. A companion mobile application provides computer-vision-based result interpretation, telehealth service connections, and hotspot mapping for tick-borne disease risk areas.

Is LymeAlert a public or private company?

LymeAlert is a private company. It is classified as venture growth investor backed and is currently operating.

When was LymeAlert founded?

LymeAlert was founded in 2024. It employs 1 to 10 people.

Where is LymeAlert based?

LymeAlert is headquartered in Cambridge, United States, in the North America region.

How does LymeAlert make money?

Three revenue lines are on record. Test Kit Hardware Sales are the primary driver. The others are telehealth Services (Potential) and data Analytics and Mapping.

Who are LymeAlert's main competitors?

Broad incumbents on record are Quest Diagnostics, Abbott, Labcorp and IGeneX. Direct peers are TickReport (UMass Amherst), Scanwell Health, TICKNOLOGY, Cue Health and Everlywell. Binx Health is listed as an emerging player.

Does LymeAlert have an API?

No public API is recorded for LymeAlert.

What industry is LymeAlert in?

LymeAlert's product category is At-Home Diagnostic Test Kits. Its primary akta.pro industry code is HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category), with a secondary code of HLAKAGAL, Tick-Borne & Vector-Borne Diseases. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebLymeAlert Expands Access to At-Home Tick Testing and Nationwide Telehealth SupportLymeAlert, a MIT-founded biotech startup, is expanding its at-home tick-testing technology and telehealth support to all 50 states. The company's Tick Crusher kit detects Borrelia burgdorferi in ticks, with a second production batch shipping in late 2026 and full delivery expected in January 2027.ventureLABDispatches from the Frontlines: Capital, Community, and Connection at Startupfest 2026ventureLAB attended Startupfest 2026 in Montréal, where 25% of the audience were investors and over $825,000 in prizes and grants were awarded. The event highlighted AI as a defensible capability and health as a key theme, with LymeAlert winning the Women in Tech Investment Prize.BostonGlobe.comLyme disease tick test: Home test kit seeks to limit spreadLymeAlert is a new at-home test kit that allows users to test ticks found on their bodies for Lyme disease bacteria in approximately 15 minutes, using a chemically infused paper strip. The product aims to help users avoid the cost and wait time associated with laboratory testing, which typically costs $50 to $450 and requires a week or more for results. Laboratories throughout the United States currently offer tick testing services as an alternative to emergency room visits after a tick bite.Castle PlacementPetTech/Pet Care Capital Raises and Investors in the U.S.This market report summarizes pet care and pet tech capital raising transactions in the U.S. for January 2026, covering multiple LBOs, early-stage VC funding, and accelerator grants. Notable transactions include BARK Inc being taken private by RRE Ventures, Resolute Ventures, Founders Circle Capital, and Ironbound Partners Fund, and Meowtel being acquired by A Place for Rover (with Blackstone as financial sponsor). Early-stage activity included LymeAlert raising venture funding from Fortify Ventures, while ChefPaw, PetPax Co., and CoVet joined Pet Care Innovation's accelerator program with grant funding.Poetsandquants2024 Most Disruptive MBA Startups: LymeAlert, MIT (Sloan)LymeAlert, founded by MIT Sloan Fellows Erin Dawicki, Brenda Ong, and Michelle Ewy, launched a home tick testing kit for early Lyme disease detection. The company raised $70,000 in non-dilutive funding and is raising a pre-seed round to begin manufacturing. Its long-term goal is to become a global leader in vector-borne disease detection.The Times of IndiaTechnology as a foundation for innovation. - The Economic TimesMeet the Drapers, a startup pitch competition, featured four entrepreneurs presenting innovations across healthtech, space technology, and fintech to judges including Tim Draper. Reaction Dynamics, a space technology company focused on satellite infrastructure, was declared the winner after presenting $10 million in private capital and $10 million in government grants. The other competing startups were LymeAlert (tick-testing kit), NORA Health AI (AI health assistant), and Takenos (cross-border payment platform for freelancers).VentureRadarTop "disease surveillance" start-upsA VentureRadar list ranks start-ups founded since 2020 under the keyword "disease surveillance," showing three companies: LymeAlert, a privately held US firm founded in 2024 offering a home immunoassay test kit for Lyme disease; RIIS Technology LLC, a US company founded in 2020 providing data architecture and analytics for government; and Nuqta Genomics, a Saudi Arabia-based privately held firm founded in 2024 offering genomics and AI-driven infectious disease diagnostics.